Prilosec

Zollinger-Ellison Syndrome, Curling Ulcer, Heartburn + 15 more
Treatment
15 FDA approvals
20 Active Studies for Prilosec

What is Prilosec

OmeprazoleThe Generic name of this drug
Treatment SummaryOmeprazole is a medication used to reduce the production of stomach acid in patients with gastrointestinal disorders. The drug was the first of its kind to be introduced in 1989 and is commonly used to treat gastroesophageal reflux disease (GERD) and peptic ulcer disease. It has been proven to be effective and well-tolerated by both children and adults and is one of the most commonly prescribed drugs for gastric acid related disorders.
Prilosecis the brand name
image of different drug pills on a surface
Prilosec Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prilosec
Omeprazole
1990
669

Approved as Treatment by the FDA

Omeprazole, otherwise called Prilosec, is approved by the FDA for 15 uses which include Gastric Ulcer and Gastro-esophageal Reflux Disease (GERD) .
Gastric Ulcer
Gastro-esophageal Reflux Disease (GERD)
Healing
multiple endocrine adenomas
Gastroesophageal Reflux
Zollinger-Ellison Syndrome
Helps manage Zollinger-Ellison Syndrome
Heartburn
Helps manage Heartburn
Stomach Ulcer
Duodenal Ulcer
Helicobacter Pylori Infection
Used to treat Helicobacter Pylori Infection in combination with Amoxicillin
Heartburn
Helps manage Heartburn
Heartburn
Erosive Esophagitis
Adenoma
Curling Ulcer

Effectiveness

How Prilosec Affects PatientsThis drug reduces the amount of acid produced in the stomach. It usually starts to work within an hour, and its effect increases with repeat daily dosing, reaching its peak after four days. Taking this drug can also increase the levels of gastrin, a hormone which can affect certain medical tests. Long-term use has not been linked to any changes in the central nervous system, cardiovascular system, or respiratory system. It also does not appear to have an effect on thyroid function, blood sugar levels, or other hormones.
How Prilosec works in the bodyHydrochloric acid (HCl) is naturally produced by stomach cells and helps create an acidic environment in the stomach. Omeprazole is a drug used to reduce the amount of HCl produced in the stomach, which helps reduce symptoms of stomach distress. It works by blocking the enzyme responsible for producing HCl, so that less acid is produced. This effect can last up to 36 hours. Omeprazole is also used to treat infections caused by the bacteria Helicobacter pylori (H. pylori). H. pylori grows best in an acidic environment, so by raising the stomach

When to interrupt dosage

The recommended dosage of Prilosec is contingent upon the diagnosed condition, such as Stomach Ulcer, Heartburn and Zollinger-Ellison Syndrome. The magnitude of dosage also relies upon the delivery technique delineated in the table below.
Condition
Dosage
Administration
Heartburn
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
hypersecretory conditions
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Mastocytosis, Systemic
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Ankylosing Spondylitis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Gastroesophageal Reflux
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Heartburn
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Prophylaxis of NSAID gastric ulceration
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Rheumatoid Arthritis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Stomach Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Helicobacter Pylori Infection
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Osteoarthritis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Zollinger-Ellison Syndrome
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Curling Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Adenoma
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Erosive Esophagitis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Stomach Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Healing
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral
Peptic Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
, Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Kit, Powder, for suspension, Powder, for suspension - Oral, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release, Tablet, Delayed Release - Oral, Tablet, orally disintegrating, delayed release, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet, Tablet - Oral, Kit - Oral, For suspension, For suspension - Oral

Warnings

Prilosec Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Omeprazole may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Omeprazole may interact with Pulse Frequency
There are 20 known major drug interactions with Prilosec.
Common Prilosec Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Omeprazole.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Omeprazole.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Omeprazole.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Omeprazole.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Omeprazole.
Prilosec Toxicity & Overdose RiskThe toxic dose of oral omeprazole in mice is 4000mg/kg and 2210mg/kg in rats. Overdosing on this drug may cause confusion, drowsiness, blurred vision, fast heartbeat, nausea, sweating, flushing, headache, and a dry mouth. In studies, rats given high doses of omeprazole developed gastric carcinoid tumors and abnormal cells in their stomachs. The drug was also found to have a positive effect on chromosomal aberrations in a few tests. It is unknown if omeprazole is present in breast milk or what its effects would be, so benefits
image of a doctor in a lab doing drug, clinical research

Prilosec Novel Uses: Which Conditions Have a Clinical Trial Featuring Prilosec?

96 active trials are currently being conducted to assess the potential of Prilosec in treating Rheumatoid Arthritis, Acid-mediated Gastroesophageal Reflux Disease and Curling Ulcer.
Condition
Clinical Trials
Trial Phases
Rheumatoid Arthritis
58 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Heartburn
15 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 1, Phase 4
Gastroesophageal Reflux
0 Actively Recruiting
Prophylaxis of NSAID gastric ulceration
0 Actively Recruiting
Mastocytosis, Systemic
0 Actively Recruiting
hypersecretory conditions
0 Actively Recruiting
Stomach Ulcer
2 Actively Recruiting
Phase 4, Not Applicable
Erosive Esophagitis
2 Actively Recruiting
Phase 2, Phase 3
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable
Stomach Ulcer
0 Actively Recruiting
Heartburn
2 Actively Recruiting
Phase 3, Not Applicable
Zollinger-Ellison Syndrome
0 Actively Recruiting
Osteoarthritis
0 Actively Recruiting
Curling Ulcer
0 Actively Recruiting
Peptic Ulcer
0 Actively Recruiting
Adenoma
0 Actively Recruiting
Healing
0 Actively Recruiting

Prilosec Reviews: What are patients saying about Prilosec?

5Patient Review
8/26/2020
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
This drug provided me instant relief from a very bad case of GERD. I've been taking it for two weeks now and have only experienced mild side effects. If these don't get worse, I would say this is a miracle drug.
5Patient Review
3/14/2021
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
This treatment is effective and does what it's supposed to do.
5Patient Review
4/11/2021
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
I have been taking this medication for about a year to treat my GERD, and it has worked wonderfully. I am now able to drink coffee without any issues, whereas before I would have to rush to the bathroom within 10-15 minutes of drinking it.
5Patient Review
8/26/2020
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
I had a very severe case of GERD and this drug provided immediate relief. I've been taking it for two weeks now with only mild side effects. If the side effects don't get worse, I would say that this is a miracle drug.
5Patient Review
4/11/2021
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
I've had great success in treating my esophageal acid reflux with this medication. I'm now able to drink coffee without any issues, where before it would come right back up.
5Patient Review
11/12/2020
Prilosec for Heartburn
I did experience some dizziness and it took about 4 days to start lessening the nausea. However, I am very pleased with this treatment overall.
5Patient Review
11/12/2020
Prilosec for Heartburn
I did experience some dizziness and it took about four days for the nausea to start subsiding.
5Patient Review
3/14/2021
Prilosec for Condition in which Stomach Acid is Pushed Into the Esophagus
This medication is effective.
2.3Patient Review
10/3/2022
Prilosec for Excessive Production of Stomach Acid
I noticed an initial improvement after starting this medication, but after five days I started feeling silly and unfocused. Additionally, I developed chest and back pain. Thankfully, these symptoms all subsided within two days of no longer taking the medication.
2.3Patient Review
10/3/2022
Prilosec for Excessive Production of Stomach Acid
At first it was effective but after five days I started feeling silly and experiencing chest and back pain. After two days of not taking the medication, I definitely noticed an improvement.
1Patient Review
6/22/2022
Prilosec for Inflammation of the Esophagus with Erosion
I took this drug for two weeks and it turned me into a different person. I was anxious, depressed, and felt tingling and sadness. I'm off the drug now, but I wonder how long the side effects will last.
1Patient Review
6/22/2022
Prilosec for Inflammation of the Esophagus with Erosion
This drug turned me into a different person. I felt anxiety, depression, tingling and sadness while taking it for two weeks. I've been off the drug for five days now and I'm wondering how long the side effects will last.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prilosec

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Prilosec used to treat?

"Prilosec OTC is a medication used to treat heartburn that occurs frequently, defined as heartburn occurring two or more days per week. Heartburn is caused by stomach contents backing up into the esophagus, and is characterized by a burning sensation in the chest."

Answered by AI

Is it OK to take Prilosec every day?

"To use Prilosec OTC, take one pill every day for 14 days. Do not take more than one pill every day or more than every 4 months unless a doctor tells you to."

Answered by AI

What is the difference between omeprazole and Prilosec?

"Omeprazole (Prilosec) is a medication that is cheap and generic that is available both over the counter and with a prescription. It belongs to a class of medications known as proton-pump inhibitors (PPIs) and is one of the most popular medications in the United States. It is used to treat heartburn, reflux disease (GERD), and ulcers."

Answered by AI

Why you should not take Prilosec?

"The dangers of taking Prilosec include an increased risk of kidney disease and long-term kidney damage. In a study of 125,000 PPI users over a five year period, researchers found that kidney problems often developed silently. Half of the people who developed chronic kidney damage had never had any kidney problems before taking PPIs."

Answered by AI

Clinical Trials for Prilosec

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Our Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What We Think: We believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What We're Doing: We will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing we'll look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. We'll also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: We've already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. We've also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, we need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Have you considered Prilosec clinical trials? We made a collection of clinical trials featuring Prilosec, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of University of California, Irvine - UCI Medical Center in Orange, United States.

Sling-Fiber Preservation vs. Conventional POEM for Achalasia

18+
All Sexes
Orange, CA
Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.
Waitlist Available
Has No Placebo
University of California, Irvine - UCI Medical CenterJason Samarasena, MD, MBA
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesHubert LimSecondWave Systems Inc.
Have you considered Prilosec clinical trials? We made a collection of clinical trials featuring Prilosec, we think they might fit your search criteria.Go to Trials
Image of Del Sol Research Management, LLC in Tucson, United States.

Linaprazan Glurate vs Lansoprazole for Acid Reflux

18 - 80
All Sexes
Tucson, AZ
The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will: * Undergo an endoscopy in the beginning and after 4 weeks of treatment * If healing is not observed, another endoscopy may be done at 8 weeks * During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies) * Have blood and urine tests at clinic visits to check overall health * Receive electrocardiograms (ECGs) to monitor heart function * Complete daily questionnaires on an electronic device about symptoms and experiences
Phase 3
Waitlist Available
Del Sol Research Management, LLC (+24 Sites)Cinclus Pharma Holding AB
Image of St. Lawrence Health in Potsdam, United States.

Primary Care for Rheumatoid Arthritis

18+
All Sexes
Potsdam, NY
Rheumatoid arthritis (RA) is a complex autoimmune disease where the immune system attacks healthy joint tissue; causing pain, swelling, and stiffness of the joints. This disease effects lots of people in the US and can lead to major joint damage if not properly treated. In rural areas like northern NY, these are underserved areas for RA patients, thus many patients struggle to get the appropriate care. This model is testing whether primary care providers (PCP) can safely and effectively provide stable RA patients with the proper treatment rather than send them to a specialist. PCPs were trained through classes, case reviews, and a final exam. Patients will be randomly assigned to either see a trained PCP or their normal rheumatologist at the rheumatology clinic. This study will examine how patients are doing over a year using medical exams and patient feedback. If this model proves to be successful, it will make RA treatment easier and more affordable for patients.
Recruiting
Has No Placebo
St. Lawrence HealthEyal Kedar, MD
Image of Pender Community Health Centre in Vancouver, Canada.

Personalized Outreach for Rheumatic Diseases

18+
All Sexes
Vancouver, Canada
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia. The main question it aims to answer are: * Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic? * Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic? The researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach. Participants will: * Undergo randomization to receive honoraria or honoraria and outreach services together * Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals * Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition
Waitlist Available
Has No Placebo
Pender Community Health CentreBrent R Ohata, MD
Have you considered Prilosec clinical trials? We made a collection of clinical trials featuring Prilosec, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security